Caspase-1 activation with concomitant degradation of cullin-1/5. by Attinder Chadha (11414273)

Subjects:

Delayed boost lowers IgG3. by LaTonya D. Williams (3140490)

“…<p><b>(A)</b> Response rate (top panel) and response magnitude (bottom panel) for HIV-1 envelope-specific IgG3 in plasma at two weeks post final RV144 vaccination (week 26) and two weeks post first and second RV305 boosts (weeks 2 and 26, respectively) against four vaccine-matched antigens (A244 D11 gp120, MN gp120, 92TH023 gp120, and AE.A244 V1V2 tags) identified as primary immune variables. …”

Binding antibody multiplex assay plasma IgG subclass (IgG1-IgG4) responses. by LaTonya D. Williams (3140490)

Characterization of endothelial cells from CTEPH patient. by William Salibe-Filho (9727738)

Delayed boosting with ALVAC-HIV/AIDSVAX B/E or AIDSVAX B/E increases IgG and IgG1 breadth. by LaTonya D. Williams (3140490)

IL-4 Causes Hyperpermeability of Vascular Endothelial Cells through Wnt5A Signaling by Tom Skaria (2733439)

“…Our study identifies Wnt5A as a novel marker of IL-4 activated vascular endothelium and demonstrates a critical role for Wnt5A in mediating IL-4 induced endothelial barrier dysfunction. …”

Antibody-dependent cellular phagocytosis (ADCP) is boosted by RV305 vaccination and is associated with IgG1 binding response. by LaTonya D. Williams (3140490)

<i>Ramp2</i> is essential for proper spiral artery remodeling. by Mahita Kadmiel (4262311)

Assessment of calcium events, pERK levels, NMDA receptor expression and extracellular zinc levels in <i>slc13a5</i> mutants. by Deepika Dogra (21072023)

“…<p><b>(A-</b>C) Quantification of the amplitude and frequency of calcium events (ΔF/F > 2) and representative single neuron calcium traces in the MB at 3 dpf. …”

Antibody-dependent cellular cytotoxicity (ADCC) activity reported as AUC. by LaTonya D. Williams (3140490)

Viral titration assays demonstrate that nitrogen gas plasma treatment of adenovirus results in a decrease in viral titer. by Akikazu Sakudo (179329)

Lack of RSC3-reactive CD4 binding site IgG antibodies elicited in RV144 and RV305. by LaTonya D. Williams (3140490)

Anti-interleukin-1 treatment in patients with rheumatoid arthritis and type 2 diabetes (TRACK): A multicentre, open-label, randomised controlled trial by Piero Ruscitti (3684799)

“…Participants in the TNFi group had a nonsignificant slight decrease of HbA1c%. Assuming the success threshold to be HbA1c% ≤ 7, we considered an absolute risk reduction (ARR) = 0.42 (experimental event rate = 0.54, control event rate = 0.12); thus, we estimated, rounding up, a number needed to treat (NNT) = 3. …”

Lesion size was significantly reduced at day 7 after laser injury in mice with sympathetic nerves blockade. by Xue Tan (2994324)

Durability of IgG3 responses. by LaTonya D. Williams (3140490)

3D representation of MeV-ΔV infected cells realized with IMARIS 9.9.1. by Pierre Khalfi (7868252)

<i>NARS2</i> structure and molecular modeling. by Mariella Simon (711384)

Subjects:

Analysis of the impact of the NARS2 mutations on mitochondrial functions. by Mariella Simon (711384)

Subjects:

Effect of point mutations on the kinase activity of c-Abl. by Nicole Dölker (641799)

“…The kinase activity was normalized to the amount of protein and to the activity of the wild-type CD or SH2-CD construct. <b>A</b> M297L was found to decrease kinase activity, whereas M297G had an activating effect in the absence of the SH2 domain. …”

Durability of Env gp120 IgG responses. by LaTonya D. Williams (3140490)